stockrow
Friday 6 November 2026
Export CLPT’s income statement to Excel — free account
ClearPoint Neuro, Inc.
CLPT Healthcare Medical Devices
ClearPoint Neuro, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $37.0 million, up 17.8% from fiscal 2024.
- Revenue
- +36.3%
- EPS
- −14.7%
- Free cash flow
- −58.1%
- Total debt
- +74.1%
Quarter to September 2026, against a year earlier
8.60
0.09
−1.04%
Follow CLPT
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
10.48 | 6.62 | 12.73 | 8.32 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(32.07) | (33.75) | (76.72) | (74.00) | |
P/B ratio |
13.82 | 14.27 | 49.94 | 13.87 | |
Price to Tangible BV |
58.46 | 0.00 | 0.00 | 51.24 | |
EV/Sales |
10.56 | 6.97 | 13.22 | 8.42 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(16.33) | (11.00) | (18.52) | (11.91) | |
EV/FCF |
(15.63) | (10.38) | (17.56) | (11.34) | |
Quick Ratio |
4.87 | 4.67 | 3.66 | 5.49 | |
Current Ratio |
5.91 | 5.79 | 4.74 | 6.76 | |
Net Debt/EBITDA |
(0.51) | (1.92) | (2.37) | (1.00) | |
Debt/Assets |
50.21% | 53.14% | 57.91% | 45.10% | |
Debt/Equity |
1.75 | 2.63 | 4.66 | 1.86 | |
Asset Turnover |
0.54 | 0.66 | 0.57 | 0.53 | |
Operating CF/Net income |
1.55 | 0.83 | 0.62 | 0.69 | |
Capex/Depreciation |
(0.06) | (0.56) | (0.15) | (0.08) | |
Interest Coverage |
(6.50) | (6.13) | (7.25) | (4.38) | |
Research and Development Expense of Revenue |
31.10% | 37.29% | 42.57% | 33.28% | |
Selling, General and Administrative Expense of Revenue |
98.10% | 96.57% | 113.25% | 77.62% | |
Intangible Assets out of Total Assets |
0.22 | 0.22 | 0.24 | 0.18 | |
Share Based Compensation of Revenue |
19.03% | 18.29% | 20.87% | 15.57% | |
Graham Net Nets |
(0.02) | (0.07) | (0.05) | (0.05) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(6.65%) | (11.10%) | (6.61%) | (9.92%) | |
Free Cash Flow Yield |
(6.45%) | (10.14%) | (5.92%) | (8.93%) | |
Revenue per Share |
0.37 | 0.41 | 0.36 | 0.39 | |
Operating CF per Share |
(0.43) | (0.27) | (0.23) | (0.16) | |
Capex per Share |
0.00 | (0.02) | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.43) | (0.29) | (0.24) | (0.17) | |
Cash per Share |
1.62 | 1.20 | 0.97 | 1.49 | |
Shareholders Equity per Share |
0.99 | 0.64 | 0.36 | 0.88 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.99 | 0.64 | 0.36 | 0.88 | |
Free Cash Flow |
(12.13) | (8.61) | (7.23) | (5.25) | |
Working Capital |
52.84 | 45.40 | 38.62 | 56.85 | |
Capital Expenditures |
(0.05) | (0.64) | (0.21) | (0.14) | |
Net Current Asset Value |
(6.13) | (19.70) | (27.03) | (18.75) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.05 | 0.02 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
5.63 | 6.16 | 6.33 | 6.01 | |
Average Payables |
1.30 | 1.77 | 1.84 | 0.89 | |
Average Inventory |
7.61 | 7.58 | 7.55 | 8.18 | |
Average Assets |
68.47 | 61.74 | 74.81 | 86.54 | |
Average Common Equity |
26.70 | 19.41 | 15.26 | 21.57 |
Columns are period end dates · fundamentals updated 2 Nov 2026